PTRH2

Across TCGA pan-cancer cohorts, PTRH2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTRH2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PTRH2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PTRH2 expression acts as an unfavorable survival marker, although some lineages such as COAD and HNSC show a favorable association.

CCRCC, COAD, and HNSC are the cancer types where PTRH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.605	1.000	.001	33	view →
COAD	DFS	Quartile	III,IV	1.000	0.802	.035	24	view →
HNSC	DFS	Median	II,III,IV	0.743	0.531	.010	14	view →
LUAD	DFS	Median	All	0.961	0.833	.023	4	view →
PDAC	DFS	Tertile	III,IV	0.975	0.624	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTRH2–CCRCC (OS)

Open the CCRCC breakdown →